CN Patent

CN116712434A — 施用某些vmat2抑制剂的方法

Assigned to Neurocrine Biosciences Inc · Expires 2023-09-08 · 3y expired

What this patent protects

提供了向有需要的患者施用选自缬苯那嗪和(+)‑α‑3‑异丁基‑9,10‑二甲氧基‑1,3,4,6,7,11b‑六氢‑2H‑吡啶并[2,1‑a]异喹啉‑2‑醇或其药物可接受的盐和/或同位素变体的囊泡单胺转运体2(VMAT2)抑制剂的方法，其中所述患者患有轻度、中度或重度肝损伤。

USPTO Abstract

提供了向有需要的患者施用选自缬苯那嗪和(+)‑α‑3‑异丁基‑9,10‑二甲氧基‑1,3,4,6,7,11b‑六氢‑2H‑吡啶并[2,1‑a]异喹啉‑2‑醇或其药物可接受的盐和/或同位素变体的囊泡单胺转运体2(VMAT2)抑制剂的方法，其中所述患者患有轻度、中度或重度肝损伤。

Drugs covered by this patent

Patent Metadata

Patent number
CN116712434A
Jurisdiction
CN
Classification
—
Expires
2023-09-08
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.